Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Advaxis Inc (ADXS)

Advaxis Inc (ADXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,544
  • Shares Outstanding, K 17,220
  • Annual Sales, $ 6,060 K
  • Annual Income, $ -66,520 K
  • 60-Month Beta 3.21
  • Price/Sales 0.11
  • Price/Cash Flow N/A
  • Price/Book 0.11
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.42
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 01/09/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/19
See More
  • Average Estimate -1.37
  • Number of Estimates 1
  • High Estimate -1.37
  • Low Estimate -1.37
  • Prior Year -4.35
  • Growth Rate Est. (year over year) +68.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.26 +56.00%
on 10/30/19
0.41 -1.13%
on 11/15/19
+0.08 (+26.00%)
since 10/15/19
3-Month
0.21 +99.66%
on 09/25/19
0.44 -7.79%
on 10/09/19
unch (-0.56%)
since 08/15/19
52-Week
0.21 +99.66%
on 09/25/19
10.80 -96.21%
on 04/01/19
-6.34 (-93.93%)
since 11/15/18

Most Recent Stories

More News
Advaxis Announces Business and Pipeline Update

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the following updates to its...

ADXS : 0.40 (+5.26%)
Advaxis and UCLA Enter Collaboration for Glioblastoma Immunotherapy Discovery Research

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a research collaboration agreement...

ADXS : 0.40 (+5.26%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

FinancialBuzz.com News Commentary

ADXS : 0.40 (+5.26%)
GERN : 1.33 (-2.92%)
SLS : 5.24 (-15.07%)
ONPH : 0.0300 (-23.08%)
Companies Turn to Advanced Therapies to Curb the Spread of Cancer

In 2019, the American Cancer Society projected 1.76 million new cancer cases diagnosed and the number of deaths to stand at 606,880 in the U.S. Overall, the alarming projection has caused concern within...

ONPH : 0.0300 (-23.08%)
KDMN : 3.86 (-1.53%)
ADXS : 0.40 (+5.26%)
SLS : 5.24 (-15.07%)
GERN : 1.33 (-2.92%)
Advaxis Announces Updated Prolonged Survival Data in Phase 1/2 ADXS-PSA Trial

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated median overall survival...

MRK : 84.97 (+0.50%)
ADXS : 0.40 (+5.26%)
Dr. Robert Petit Follows His Passion to OS Therapies as Chief Medical & Scientific Advisor

OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS), today announced the appointment of Robert Petit,...

ADXS : 0.40 (+5.26%)
Advaxis: Fiscal 3Q Earnings Snapshot

PRINCETON, N.J. (AP) _ Advaxis Inc. (ADXS) on Monday reported a loss of $9.9 million in its fiscal third quarter.

ADXS : 0.40 (+5.26%)
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline...

ADXS : 0.40 (+5.26%)
Advaxis, Inc. Issues Letter to Shareholders

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its chief executive officer,...

ADXS : 0.40 (+5.26%)
BriaCell Appoints Richard J. Berman to Board of Directors

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced...

IMRN : 3.51 (-0.28%)
BCT.VN : 0.050 (+11.11%)
BCTXF : 0.0378 (-3.08%)
ADXS : 0.40 (+5.26%)
CYRX : 15.44 (+3.28%)
BIVI : 0.0400 (-28.57%)
CATS : 15.32 (-1.79%)
MRK : 84.97 (+0.50%)
INCY : 86.57 (+0.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADXS with:

Business Summary

Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence...

See More

Key Turning Points

2nd Resistance Point 0.41
1st Resistance Point 0.39
Last Price 0.40
1st Support Level 0.36
2nd Support Level 0.33

See More

52-Week High 10.80
Fibonacci 61.8% 6.75
Fibonacci 50% 5.50
Fibonacci 38.2% 4.25
Last Price 0.40
52-Week Low 0.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar